CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Issue Information	44
Issue Information	42
Issue Information	41
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	34
Pharmacometric and statistical considerations for dose optimization	30
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	28
Issue Information	28
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	27
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr	26
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	26
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	26
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	25
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	25
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	25
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	24
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	24
Issue Information	23
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	23
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	23
Evaluation of covariate effects in item response theory models	22
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization	22
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	21
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	21
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation	21
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease	21

Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	20
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	20
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	20
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	19
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	19
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	19
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	19
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	19
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	18
Application of a dual mechanistic approach to support bilastine dose selection for older adults	18
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors	18
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	17
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing	17
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution	17
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine	17
Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling	17
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	16
Issue Information	16
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	16
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	16
Impact of Mechanistic Modeling and Simulation Methodologies on Product‐Specific Guidance Development for Non‐Orally Administered Drug Products	16
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples	16
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report	16
Issue Information	16
Mechanistic pharmacokinetic–pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression	15
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis	15
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy	15
CYTOCON: The manually curated database of human in vivo cell and molecule concentrations	15
A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO	15
Metaheuristics for pharmacometrics	14
Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma	14
Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality	14
	14
Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel	14
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries	14
	14
Activity and perspective on quantitative modeling and simulation in Japan: Update from the Pharmaceuticals and Medical Devices Agency	13
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I	13
Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia	13
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials	13
Variable or variate? A conundrum in pharmacometrics exposure–response models	13
Tutorial for Modeling Delays in Biological Systems in the NONMEM Software	13
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin	13
Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles	13
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact	13
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection	12
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study	12
	12
	12
	12

Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions	12
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager g	12
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials	12
Issue Information	12
Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine	12
Development of and insights from systems pharmacology models of antibody‐drug conjugates	12
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling	11
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials	11
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps	11
Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development	11
The influence of flip‐flop in population pharmacokinetic analyses	11
A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab	11
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases	11
Low‐dimensional neural ordinary differential equations accounting for inter‐individual variability implemented in Monolix and NONMEM	11
Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer	11
Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients	11
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates	10
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B	10
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling	10
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach	10
Issue Information	10
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview	10
Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy	10
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases	10
Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine	10
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus	10
Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method	10
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool	10
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?	9
Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody	9
Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)	9
Machine Learning‐Based Model Selection and Averaging Outperform Single‐Model Approaches for a Priori Vancomycin Precision Dosing	9
Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application	9
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions	9
Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias	9
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model	9
A literature review of drug transport mechanisms during lactation	9
Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model	9
Issue Information	9
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach	9
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer	9
Within‐chain parallelization—Giving Stan Jet Fuel for population modeling in pharmacometrics	9
Quantitative approaches to drug safety: The 2022 PSP special issue	9
	9
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases	9
Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma	9
State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases	9
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Adults With Chronic Alcohol	9
Quantitative systems pharmacology in the age of artificial intelligence	9
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin	9
Issue Information	9
Issue Information	9
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children	9
Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points	8
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example	8
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans	8
Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus	8
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients	8
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling	8
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	8
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework	8
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19	8
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective	8
The area under the effect curve as an efficacy determinant for anti‐infectives	8
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach	8
Issue Information	8
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	8
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors	8
Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools	8
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?	8
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections	8
A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings	8
	8
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	8
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	8
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	7
A fully automatic tool for development of population pharmacokinetic models	7
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	7
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor	7
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study	7

Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	7
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	7
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	7
Mechanistic modeling of drug products applied to the skin: A workshop summary report	7
	7
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	7
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	7
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	7
Issue Information	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
Delineating gene–environment effects using virtual twins of patients treated with clozapine	7
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	7
Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model	7
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	7
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	7
	7
Abstracts	7
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms	7
Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency	6
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV	6
Multistate modeling for survival analysis in critically ill patients treated with meropenem	6
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer	6
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor‐Associated Macrophages and Microglia to Treat Glioblastoma	6
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	6
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development	6
Issue Information	6
Preclinical side effect prediction through pathway engineering of protein interaction network models	6
Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic‐Pharmacodynamic and Machine Learning Analyses	6
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability	6
Population pharmacokinetics of favipiravir in patients with COVID‐19	6
Growth‐rate model predicts in vivo tumor response from in vitro data	6
A continued learning approach for model‐informed precision dosing: Updating models in clinical practice	6
Issue Information	6
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	6
PBPK perspective on alternative CYP3A4 inducers for rifampin	6
Corrigendum to: 2022 WCoP Abstracts	6
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report	6
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody	6
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology	6
Application of longitudinal item response theory models to modeling Parkinson’s disease progression	6
A quantitative systems pharmacology approach to predict the safe‐equivalent dose of doxorubicin in patients with cardiovascular comorbidity	6
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life	6
Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	6
Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches	6
	6
Issue Information	6
Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm	6
Mixed‐effects models and the drug titration paradox	6
A framework to guide dose & regimen strategy for clinical drug development	6
In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics	6
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis	6
CKD subpopulations defined by risk‐factors: A longitudinal analysis of electronic health records	6
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC	5
Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework	5
Development and application of a PBPK modeling strategy to support antimalarial drug development	5
Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach	5
Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility	5
Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes	5
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19	5
To be or not to be, when synthetic data meet clinical pharmacology: A focused study on pharmacogenetics	5
Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers	5
Biased computation of probability of target attainment for antimicrobial drugs	5
Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic	5
	5
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide	5
Model‐based prediction of progression‐free survival for combination therapies in oncology	5
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors	5
Computational design of clinical trials using a combination of simulation and the genetic algorithm	5
Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma	5
Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance	5
Evaluation of machine learning methods for covariate data imputation in pharmacometrics	5
Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator	5
Introduction of an artificial neural network–based method for concentration‐time predictions	5
	5
Two new user‐friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales	5
Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine	5
Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids	5
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis	5
Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups	5
Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV‐2 patients	5
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat	5
	5
Consistent methods for fat‐free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults	5
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction	5
	5
A network paradigm predicts drug synergistic effects using downstream protein–protein interactions	5
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data	5
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol	5
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models	4
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report	4
Development of a Heuristic Machine Analogy Method for Model Simplification With an Application to a Large‐Scale Model of Gi/Gs Signaling	4
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	4
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	4
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	4
Tumor growth inhibition modeling to support the starting dose for dacomitinib	4